These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 7671257)

  • 1. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
    Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
    Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.
    Lowe SL; Rubinchik S; Honda T; McDonnell TJ; Dong JY; Norris JS
    Gene Ther; 2001 Sep; 8(18):1363-71. PubMed ID: 11571575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
    Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
    Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.
    Fraizer G; Leahy R; Priyadarshini S; Graham K; Delacerda J; Diaz M
    Int J Oncol; 2004 Mar; 24(3):461-71. PubMed ID: 14767530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
    Guo Y; Kyprianou N
    Cancer Res; 1999 Mar; 59(6):1366-71. PubMed ID: 10096572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo.
    Burchardt T; Burchardt M; Chen MW; Cao Y; de la Taille A; Shabsigh A; Hayek O; Dorai T; Buttyan R
    J Urol; 1999 Nov; 162(5):1800-5. PubMed ID: 10524938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
    Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
    Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
    Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
    Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T; Lin FF; Rao P; Lin MF
    Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
    Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
    Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.
    Lee SO; Dutt SS; Nadiminty N; Pinder E; Liao H; Gao AC
    Prostate; 2007 Sep; 67(12):1293-300. PubMed ID: 17626246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
    Siu SW; Lau KW; Tam PC; Shiu SY
    Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of Bcl-2 during androgen-unresponsive progression of prostate cancer.
    Rothermund CA; Kondrikov D; Lin MF; Vishwanatha JK
    Prostate Cancer Prostatic Dis; 2002; 5(3):236-45. PubMed ID: 12496988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
    Gleave ME; Hsieh JT; Wu HC; von Eschenbach AC; Chung LW
    Cancer Res; 1992 Mar; 52(6):1598-605. PubMed ID: 1371718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells.
    Lee SO; Pinder E; Chun JY; Lou W; Sun M; Gao AC
    Prostate; 2008 Jan; 68(1):85-91. PubMed ID: 18008330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor.
    Eder IE; Hoffmann J; Rogatsch H; Schäfer G; Zopf D; Bartsch G; Klocker H
    Cancer Gene Ther; 2002 Feb; 9(2):117-25. PubMed ID: 11857028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a hammerhead ribozyme against BCL-2. II. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents.
    Dorai T; Goluboff ET; Olsson CA; Buttyan R
    Anticancer Res; 1997; 17(5A):3307-12. PubMed ID: 9413164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
    Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcl-2 antagonizes the combined apoptotic effect of transforming growth factor-beta and dihydrotestosterone in prostate cancer cells.
    Bruckheimer EM; Kyprianou N
    Prostate; 2002 Oct; 53(2):133-42. PubMed ID: 12242728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.